462 results on '"Mayer, Erica L."'
Search Results
2. A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer
3. Racial and Ethnic Disparities in Outcomes After Breast-Conserving Therapy and Endocrine Therapy for DCIS: A Post-Hoc Analysis of the NSABP B-35 Randomized Clinical Trial
4. Racial Disparities in Locoregional Recurrence in Postmenopausal Patients with Stage I–III, Hormone Receptor-Positive Breast Cancer Enrolled in the NSABP B-42 Clinical Trial
5. Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes
6. The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer
7. New Developments in Systemic Management for High-Risk Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer
8. ASO Visual Abstract: Racial and Ethnic Disparities in Outcomes after Breast-Conserving Therapy and Endocrine Therapy for DCIS—A Post Hoc Analysis of the NSABP B-35 Randomized, Clinical Trial
9. ASO Visual Abstract: Racial Disparities in Locoregional Recurrence in Postmenopausal Patients with Stage I–III, Hormone Receptor-Positive Breast Cancer Enrolled in the NSABP B-42 Clinical Trial
10. Disease-free survival as a surrogate for overall survival in HR+/HER2– early breast cancer: A correlation analysis
11. Single duplex DNA sequencing with CODEC detects mutations with high sensitivity
12. Mechanisms of Resistance to CDK4/6 Inhibitors in Hormone Receptor-Positive (HR +) Breast Cancer: Spotlight on Convergent CDK6 Upregulation and Immune Signaling
13. TBCRC 058: A randomized phase II study of enzalutamide, enzalutamide with mifepristone, and treatment of physician’s choice in patients with androgen receptor-positive metastatic triple-negative or estrogen receptor-low breast cancer (NCT06099769).
14. Comparison of expert treatment recommendations versus community healthcare providers: Analysis from an online decision support tool for metastatic breast cancer.
15. Disparities in patients with HER2-positive breast cancer receiving optimal treatment: Analysis of the real-world ASCO CancerLinQ dataset.
16. Analysis of the sensitivity to endocrine therapy (SET) assay in the PALLAS adjuvant trial of palbociclib in HR+/HER2- breast cancer (ABCSG-42/AFT-05/BIG-14-13).
17. Correlation of TILs indices generated by visual review and digital computational algorithm with outcomes from preoperative chemotherapy for TNBC in TBCRC 030.
18. Emerging Targeted Therapies for Early Breast Cancer
19. ‘ADVANCE’ (a pilot trial) ADjuVANt chemotherapy in the elderly: Developing and evaluating lower-toxicity chemotherapy options for older patients with breast cancer
20. Outcomes after treatment of breast cancer during pregnancy including taxanes and/or granulocyte colony-stimulating factor use: findings from a multi-institutional retrospective analysis
21. PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor–Negative...
22. Association of N-terminal pro–brain natriuretic peptide with survival among US cancer survivors.
23. Adjuvant platinum versus capecitabine for residual, invasive, triple‐negative breast cancer: Patient‐reported outcomes in ECOG‐ACRIN EA1131
24. Taxanes for the treatment of breast cancer during pregnancy: an international cohort study
25. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study
26. Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer
27. A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer
28. A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer
29. ASO Visual Abstract: Racial and Ethnic Disparities in Outcomes after Breast-Conserving Therapy and Endocrine Therapy for DCIS—A Post Hoc Analysis of the NSABP B-35 Randomized, Clinical Trial
30. ASO Visual Abstract: Racial Disparities in Locoregional Recurrence in Postmenopausal Patients with Stage I–III, Hormone Receptor-Positive Breast Cancer Enrolled in the NSABP B-42 Clinical Trial
31. Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial
32. Future Clinical and Professional Directions in Cardio-oncology
33. Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance)
34. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
35. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
36. Taxanes for the treatment of breast cancer during pregnancy: an international cohort study.
37. Racial and Ethnic Disparities in Locoregional Recurrence Among Patients With Hormone Receptor–Positive, Node-Negative Breast Cancer
38. TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer
39. Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment
40. Clonal Hematopoiesis in Older Patients with Breast Cancer Receiving Chemotherapy
41. Supplementary Figure from Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers
42. Supplementary Table from Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers
43. Supplementary Figure 4 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
44. Supplementary Figure from Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer
45. Supplementary Data from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
46. Supplementary Figure 1 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
47. Supplementary Figure 5 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
48. Supplementary Figure 8 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
49. Supplementary Table 4 from Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers
50. Supplementary Figure 3 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.